SKI Market

A+| A| A-|

Indian Indices

Sensex

75,653.04 -362.24
( -0.48%)

Global Indices

Nasdaq

49,723.13 92.96
(0.19%)

Dow Jones

7,432.82 12.89
(0.17%)

Hang Seng

62,457.26 -256.39
(-0.41%)

Nikkei 225

10,269.73 36.66
(0.36%)

Forex

USD-INR

94.41 0.04
(0.04%)

EUR-INR

111.23 0.30
(0.27%)

GBP-INR

128.63 0.31
(0.24%)

JPY-INR

0.60 0.00
(-0.10%)

YOU ARE HERE :
HOME
Markets
Equity
Company News

EQUITY - MARKET SCREENER

Marksans Pharma Ltd

Industry : Pharmaceuticals - Indian - Formulations

BSE Code

ISIN Demat

Book Value()

524404

INE750C01026

32.9918134

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

MARKSANS

37.35

9208.29

EPS(TTM)

Face Value()

Div & Yield %

5.44

0.39

Date	Headline
05-Feb-2026	Marksans Pharma gains after Q3 PAT rises 8% YoY to Rs 113 crore
05-Feb-2026	Marksans Pharma consolidated net profit rises 8.26% in the December 2025 quarter
27-Jan-2026	Marksans Pharma incorporates two subsidiaries in Ireland and Canada
10-Jan-2026	Marksans Pharma to announce Quarterly Result
20-Nov-2025	Relonchem receives UK MHRA's approval for Cetirizine Dihydrochloride 1 mg/ml Oral Solution
19-Nov-2025	Marksans Pharma receives USFDA approval for Loperamide Hydrochloride tablets
19-Nov-2025	Marksans Pharma’s arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets
17-Nov-2025	Relonchem receives UK MHRA's marketing approval for two products
14-Nov-2025	Marksans Pharma consolidated net profit rises 1.58% in the September 2025 quarter
10-Nov-2025	Barometers trade with strong gains; consumer durable shares rally

<< < 1 2 > >>

75,653.04 -362.24 ( -0.48%)

49,723.13 92.96 (0.19%)

7,432.82 12.89 (0.17%)

62,457.26 -256.39 (-0.41%)

10,269.73 36.66 (0.36%)

94.41 0.04 (0.04%)

111.23 0.30 (0.27%)

128.63 0.31 (0.24%)

0.60 0.00 (-0.10%)